The Phase 2 randomized, double-blind, placebo-controlled clinical trial was conducted by Vincentage to investigate the ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...

The substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseases SYDNEY, AUSTRALIA, June 23, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; ...

AnswersNow, the leader in virtual Applied Behavioral Analysis (ABA) therapy, today announced that Ernst & Young LLP (EY) has named its CEO Jeff Beck a 2025 Entrepreneur of the Year Mid-Atlantic Region ...

“I’m delighted to welcome Anne Marie Cook to Phathom. Her experience and broad skills will be highly impactful as we work to build Phathom into a leading GI company in the coming years,” said Steven ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies ...

KIRKLAND, Wash., June 23, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced that the company will be ...

MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it has submitted the clinical trial protocol ...

Our continued and expanded relationship with Tilde demonstrates their confidence in Optime Care’s ability to meet the needs of specialty patient populations through highly-personalized programs, ...

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with ...

The aggregate gross proceeds to the Company of this offering are expected to be approximately $2.0 million, before deducting the offering expenses payable by the Company. The Company currently intends ...